Concepedia

Ernestina Tetteh

ET

Statistics

Publications

6

Citations

625

H-Index

6

Active since

2012

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Royal Marsden NHS Foundation Trust

South Texas Accelerated Research Therapeutics

Moffitt Cancer Center

Institute of Cancer Research

Ernestina Tetteh is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and cancer pharmacology.

Publications per year

2012–2014

6

Publications

6

Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors

L. Rhoda Molife, Yan Li, Joanna Vitfell-Rasmussen et al. · Journal of Hematology & Oncology · 2014 · 190 citations · Full text

, , +17

Antitumor Activity in <i>RAS</i> -Driven Tumors by Blocking AKT and MEK

Anthony W. Tolcher, Khurum Khan, Michael Ong et al. · Clinical Cancer Research · 2014 · 137 citations · Full text

, , +16

A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors

Clifford A. Hudis, Charles Swanton, Yelena Y. Janjigian et al. · Breast Cancer Research · 2013 · 105 citations · Full text

, , +17

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

Timothy A. Yap, Yan Li, Amita Patnaik et al. · Clinical Cancer Research · 2014 · 79 citations

, , +17

Safety, Tolerability and Pharmacokinetics of Doravirine, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, after Single and Multiple doses in Healthy Subjects

Matt S. Anderson, Jocelyn Gilmartin, Caroline Cilissen et al. · Antiviral Therapy · 2014 · 78 citations · Full text

, , +17

1–5 of 6